Chest X-ray prior to biological treatment in inflammatory bowel diseases: it is not only about tuberculosis – a case report and literature review

View at publisher Summarise with VIRAT
Authors: Ida Malene Hagbard Binder, Jørn Brynskov, Mohamed Attauabi
Cited by: 0
References: 17

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

BACKGROUND: Biological treatments have substantially improved management of inflammatory bowel disease, but their profound immunosuppressive effects necessitate infection screening before initiation. Current guidelines recommend chest X-ray (CXR) alongside Mycobacterium tuberculosis testing. While this approach is widely accepted, the necessity of routine CXR in patients without tuberculosis (TB) risk factors has recently been questioned in low-incidence regions. METHODS: We report a rare case of a patient with ulcerative colitis undergoing routine preinfliximab CXR revealing an apical right-lung infiltrate, that was not suspected based on clinical assessment and negative interferon-gamma release assays testing. In addition, we summarize the existing literature on invasive aspergillosis associated with tumor necrosis factor alpha inhibitors. RESULTS: The patient had minimal clinical symptoms of pulmonary infection and remained afebrile with consistently normal C-reactive protein levels. Nevertheless, routine pretreatment CXR demonstrated an apical right-lung infiltrate, leading to cancelation of planned infliximab initiation. Subsequent analyses of bronchoalveolar fluid and sputum identified two strains of Aspergillus fumigatus . Despite prolonged antifungal therapy, the patient ultimately required a right-lung lobectomy. A comprehensive literature review identified three fatal cases of invasive aspergillosis following tumor necrosis factor alpha inhibitors, underscoring the clinical importance of detecting serious pulmonary infections prior to treatment initiation. CONCLUSIONS: Our case is, to our knowledge, the first report in inflammatory bowel disease to illustrate that CXR may uncover potentially life-threatening infections beyond TB in patients with limited clinical and biochemical signs of infection, supporting its continued role in prebiologic treatment workflows even in low-TB prevalence settings.

Fields of Study & Subjects

Inflammatory Bowel Disease Antifungal resistance and susceptibility Rheumatoid Arthritis Research and Therapies

Publication details

Journal / source
European Journal of Gastroenterology & Hepatology
Volume
38
Issue
7
Pages
836–839
Publication date
23 March 2026
Language
EN